$IVST However, Mr. Chan notes that he sees a vast majority of the biotech innovation being accomplished by small- and mid-cap stocks. While larger stocks will serve as better valuation-based opportunities, according to the fund manager. Mr. Chan notes that “the outlook of the small and mid-cap names is as exciting as it’s ever been,” as drug cycles and patent cliffs draw near for larger biotech companies.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.